Robert Blaustein, M.D., Ph.D., has served as our Chief Development Officer since January 2025. With significant depth of experience in cardiovascular drug development, Dr. Blaustein was most recently Associate Vice President at Merck, and the Atherosclerosis Section Head in the Atherosclerosis and Metabolism Clinical Research Department, leading all late phase development efforts in the Atherosclerosis space. During his 15+ years at Merck Dr. Blaustein contributed to clinical programs across a range of cardiovascular targets and led clinical development in the atherosclerosis and heart failure spaces. Dr. Blaustein obtained his undergraduate degree in mathematics from Wesleyan University. His post-graduate training included a medical residency at Brigham and Women’s Hospital, cardiology fellowship training at Massachusetts General Hospital, and a post-doctoral fellowship in the lab of Chris Miller, an HHMI investigator in the Biochemistry Department at Brandeis University. He then joined the faculty of Tufts Medical Center running an R01-funded laboratory studying ion channel proteins. At Tufts he served as an attending cardiologist in the Cardiology Division, was a faculty member in the Neuroscience and Biochemistry Departments and was co-director of the medical school’s MD-PhD Medical Scientist Training Program.

Michael Carruthers has served as our Chief Financial Officer since September 2020. Mr. Carruthers has over 20 years of experience serving as Chief Financial Officer for publicly-traded biopharmaceutical companies, with extensive experience across corporate finance and strategic planning including IPOs, secondary offerings and M&A transactions. Most recently, Mr. Carruthers consulted as Chief Financial Officer for several private and public companies. Previously, Mr. Carruthers served as Interim President of Nivalis Therapeutics, a publicly traded company acquired by Alpine Immune Sciences, in 2017 and Chief Financial Officer and Secretary from 2015 to 2017. From 1998 to 2015, he served as Chief Financial Officer for Array BioPharma Inc., a publicly traded company acquired by Pfizer Inc. Prior to this, he served as Chief Financial Officer of Sievers Instruments, Treasurer and Controller for the Waukesha division of Dover Corporation and Accountant with Coopers & Lybrand. Mr. Carruthers serves on the boards of Elevation Oncology (Nasdaq: ELEV) and OnKure, Inc., . Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.

Behrad Derakhshan, Ph.D. has served as our Chief Operating Officer since 2025, after joining Edgewise in 2020 as Chief Business Officer. Dr. Derakhshan leads Edgewise’s efforts in strategic planning, business development, commercial planning and operations, capital formation, investor relations and corporate communications. Prior to joining Edgewise, he was Chief Business Officer at VectivBio after having served as the Head of Business Development at Therachon, until its acquisition by Pfizer Inc. in 2019 for $810 million. Prior to Therachon, Dr. Derakhshan was responsible for Business Development and Strategic Evaluation at Alexion. Earlier in his career, Dr. Derakhshan worked in management consulting with a focus on rare disease drug development. Dr. Derakhshan serves on the board of Innoskel, a private biotechnology company developing therapies for rare bone diseases. Dr. Derakhshan conducted his postdoctoral training at the Yale School of Medicine and received his Ph.D. in biochemistry from a joint program between Weill Cornell Medicine, New York and the University of Surrey, UK.

Joanne M. Donovan, M.D., Ph.D., has served as our Chief Medical Officer since 2021. Most recently, Dr. Donovan served as Chief Medical Officer and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals. Since 1989, she has been a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held an appointment at Harvard Medical School since 1990, most recently as associate clinical professor of medicine. From 1998 to 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, which she joined through its acquisition of GelTex Pharmaceuticals. Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women’s Hospital.